Sustained Increase of HDL Cholesterol Over a 72-Week Period in HIV-Infected Patients Exposed to an Antiretroviral Regimen Including Lopinavir/Ritonavir

Abstract

Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multicenter, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir, an early and sustained increase of high-density lipoprotein cholesterol was observed over a 72-week period. This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks.

Keywords

lopinavir plasma concentration antiretroviral drug HIV high-density lipoprotein cholesterol dyslipidemia

References

Palella FJ Jr , Baker RK , Moorman AC , et al, and HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study . J Acquir Immune Defic Syndr. 2006;43:27-34.

Friis-Møller N. , Reiss P. , Sabin CA , et al, and DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-1735.

Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf .

Barter P. , Gotto AM , LaRosa JC , et al, and the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.

Eron J. Jr , Yeni P. , Gathe J. Jr , et al, and KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial . Lancet. 2006;368:476-482.

Walmsley S. , Bernstein B. , King M. , et al. and the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection . N Engl J Med. 2002;346:2039-2046.

Asztalos BF , Schaefer EJ , Horvath KV , et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006;184:72-77.

Stein JH , Klein MA , Bellehumeur JL , et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction . Circulation. 2001;104:257-262.

Montes ML , Pulido F. , Barros C. , et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ ritonavir-based HAART: frequency, characterization and risk factors . J Antimicrob Chemother. 2005;55:800-804.

10.

Visnegarwala F. , Maldonado M. , Sajja P. , et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004;49:283-290.

11.

Shafran SD , Mashinter LD , Roberts SE The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations . HIV Med. 2005;6:421-425.

12.

DeJesus E. , Ortiz R. , Khanlou H. , et al. Efficacy and safety of darunavir/ritonavir vs lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at Week 48: ARTEMIS. Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, Illinois. Abstract H-718b.

13.

El-Sadr WM , Lundgren JD , Neaton JD , et al, and Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.

14.

15.

Madruga JR , Cassetti I. , Suleiman JM , et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials . 2007;8:381-390.